An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Vannabouathong C, Crotty C, Le K, et al.; Authors. Current Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists: Report [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep.
| Generic name | Brand name | Dosing information |
|---|---|---|
| Liraglutide | Victoza | Starting dose: 0.6 mg daily for at least one week Maintenance dose 1: escalate to a maintenance dose of 1.2 mg daily Maintenance dose 2: escalate to a maintenance dose of 1.8 mg daily after a minimum of one week on 1.2 mg and if additional glycemic control is required |
| Saxenda | Starting dose: 0.6 mg daily Maintenance dose: escalate to a maintenance dose of 3.0 mg daily at week 5 | |
| Semaglutide | Ozempic | Starting dose: 0.25 mg weekly Maintenance dose 1 (at initial approval): escalate to a maintenance dose of 0.5 mg weekly at week 5 Maintenance dose 2 (at initial approval): option to escalate to a maintenance dose of 1.0 mg weekly after a minimum of 4 weeks on 0.5 mg and if additional glycemic control is required Maintenance dose 3 (as of January 2022): option to escalate to a maintenance dose of 2.0 mg weekly after a minimum of 4 weeks on 1.0 mg and if additional glycemic control is required |
| Wegovy | Starting dose: 0.25 mg weekly Maintenance dose: escalate to a maintenance dose of 2.4 mg weekly at week 17 |
GLP-1 = glucagon-like peptide-1; RA = receptor agonist; T2DM = type 2 diabetes mellitus.
From: Current Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
